Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Journey Medical (DERM) Net Income towards Common Stockholders: 2020-2024

Historic Net Income towards Common Stockholders for Journey Medical (DERM) over the last 5 years, with Dec 2024 value amounting to -$14.7 million.

  • Journey Medical's Net Income towards Common Stockholders rose 3.14% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.5 million, marking a year-over-year increase of 53.41%. This contributed to the annual value of -$14.7 million for FY2024, which is 280.79% down from last year.
  • Latest data reveals that Journey Medical reported Net Income towards Common Stockholders of -$14.7 million as of FY2024, which was down 280.79% from -$3.9 million recorded in FY2023.
  • Journey Medical's 5-year Net Income towards Common Stockholders high stood at $4.9 million for FY2020, and its period low was -$44.0 million during FY2021.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$14.7 million (2024), whereas its average is -$16.1 million.
  • Per our database at Business Quant, Journey Medical's Net Income towards Common Stockholders crashed by 989.13% in 2021 and then spiked by 87.00% in 2023.
  • Over the past 5 years, Journey Medical's Net Income towards Common Stockholders (Yearly) stood at $4.9 million in 2020, then crashed by 989.13% to -$44.0 million in 2021, then soared by 32.65% to -$29.6 million in 2022, then surged by 87.00% to -$3.9 million in 2023, then crashed by 280.79% to -$14.7 million in 2024.